ѰҽÎÊÒ©Íø >> ÕýÎÄ
È©ÌÇ»¹Ôø»ùÒò(AC)n¶þºËÜÕËá´®ÁªÖظ´ÐòÁв»Í¬µÈλ»ùÒòµÄɸѡ
À´Ô´£ºÑ°Ò½ÎÊÒ©Íø¡¡Ñ°Ò½ÎÊÒ©Íø
µ¥Î»£ºÀîÇå½â(ÉúÎﻯѧ½ÌÑÐÊÒ ³¤É³ 410078)£»ËÎ»ÝÆ¼(ÉúÎﻯѧ½ÌÑÐÊÒ ³¤É³ 410078)
¹Ø¼ü´Ê£ºÎ¢ÎÀÐÇÐòÁУ»µÈλ»ùÒò£»È©ÌÇ»¹Ôø£»»ùÒò
ºþÄÏÒ½¿Æ´óѧѧ±¨000103 Õª Òª£ºÑо¿ÁËÈ©ÌÇ»¹Ôø»ùÒòת¼ÆðʼµãÉÏÓÎ-2.1kb´¦µÄ΢ÎÀÐÇDNA±ê¼Ç--(AC)n¶þºËÜÕËá´®ÁªÖظ´ÐòÁÐ7ÖÖµÈλ»ùÒò(Z+6£¬Z+4£¬Z+2£¬Z£¬Z-2£¬Z-4ºÍZ-6)µÄɸѡ·½·¨¡£Ê×ÏÈ×ÔÈËÍâÖÜѪÌáÈ¡»ùÒò×éDNAºóÉè¼ÆÒ»¶ÔÒýÎï½øÐÐPCRÀ©Ôö£¬»ñµÃ³¤¶ÈΪ132¡«144bpµÄDNAƬ¶Î¡£Ñ¡È¡µÈλ»ùÒòΪ´¿ºÏ×ӵĸöÌåDNA±ê±¾µÄPCRÀ©Ôö²úÎ¾´¿»¯ºóÖ±½Ó²âÐòÒÔÈ·¶¨µÈλ»ùÒòµÄÖÖÀࣻ²¢ÒÔÈ·¶¨µÄµÈλ»ùÒòΪ±ê×¼£¬ÓÃÄòËØ/¼×õ£°·¾Û±ûÏ©õ£°·Äý½ºµçÓ¾£þÒøÈ¾ÏÔÉ«·¨¶Ô¸÷ÖÖµÈλ»ùÒò½øÐÐɸѡ¡£¸Ã·¨²Ù×÷¼ò±ã¡¢¿ìËÙ¡¢×¼È·¶È¸ß£¬ÀûÓÚ´óÁ¿±ê±¾µÄɸѡ£¬Ò²ÊÊÓÃÓÚÆäËü¶þºËÜÕËáÖØ¸´ÐòÁеÈλ»ùÒòµÄɸѡ¡£
·ÖÀàºÅ£ºQ523 ÎÄÏ×±êʶÂ룺A
ÎÄÕ±àºÅ£º1000-5625(2000)01-0009-03
Screening of all types of alleles of (A-C)n dinucleotide tandem repeat
sequence of aldose reductase gene
LI Qing-jie, SONG Hui-ping
(Department of Biochemistry, Hunan Medical University Changsha 410078)
Abstract£ºThe screening method of seven alleles (Z-6,Z-4,Z -2,Z,Z+2,Z+4 and Z+6) in the (A-C)n dinucleotide tandem repeat sequence was st udied. These alleles constitute a microsatellite DNA marker upstream of the tran scription initiation site on the aldose reductase gene. At first, genomic DNAs w ere isolated from leucocyte pellets, and the region containing the dinucleotide repeats was amplified by PCR with a pair of amplification primers that flanked 1 32¡«144bp region. Then, the PCR products of the DNA samples whose alleles belo nged to homozygotes were selected, purified, and sequenced directly in order to find out the types of alleles. Finally, using Z-2 allele as a marker, the sampl es containing Z-2 allele were detected by 12% fromamide-urea gel electrophores is together with silver-staining. This method is simple, quick and accurate. It facilitates the screening of a large number of samples and is also suitable for identification of other dinucleotide tandem repeat sequences.
Key words£ºmicrosatellite DNA;alleles;aldose reductase;gene¡ø
΢ÎÀÐÇDNA(microsatellite DNA)Ò»°ã¾ßÓи߶ȶà̬ÐÔ£¬³£×÷Ϊ»ùÒòÓë¼²²¡Ïà¹ØÐÔÑо¿µÄ±ê¼Ç¡£×÷Ϊ¶àÔª´¼Í¾¾¶µÄÏÞËÙø£¬È©ÌÇ»¹Ôø(aldose reductase, AR, EC1.1.1.21)±»ÈÏΪÓëÌÇÄò²¡ÂýÐÔ²¢·¢Ö¢Óйء£ÒÑ·¢ÏÖÔÚÈ©ÌÇ»¹Ôø»ùÒò ת¼ÆðʼµãÉÏÓÎ-2.1kb´¦¾ßÓÐÒ»¸ö΢ÎÀÐÇDNA±ê¼Ç--(AC)n¶þºËÜÕËá´®ÁªÖظ´ÐòÁÐ [1]¡£KoµÈ¶ÔÏã¸ÛµÄÖйúÈË[1]ÒÔ¼°HeesomµÈ¶ÔÓ¢¹ú°×ÈË[2]µÄÑо¿·¢ ÏÖ£¬(AC)nÖØ¸´ÐòÁÐÓÐ7ÖÖµÈλ»ùÒò£¬¼´Z+6£¬Z+4£¬Z+2£¬Z£¬Z-2£¬Z-4ºÍZ-6£¬¶ÔÓ¦µÄÖØ¸´ ÊýÄ¿n·Ö±ðΪ27£¬26£¬25£¬24£¬23£¬22ºÍ21¡£KoµÈ·¢ÏÖ£¬ÖйúÈË2ÐÍÌÇÄò²¡(NIDDM)»¼ÕßÖÐZ- 2µÈλ»ùÒò³öÏÖ³öÁ¬Ëø²»Æ½ºâ£»HeesomµÈÔò·¢ÏÖÓ¢¹ú°×ÈË1ÐÍÌÇÄò²¡(IDDM)»¼ÕßÖÐZ+2µÈλ»ù Òò±íÏÖ³öÁ¬Ëø²»Æ½ºâ¡£Òò¶øÌáʾÖйúÈ˾ßÓÐZ-2µÈλ»ùÒòµÄNIDDM»¼ÕߺÍÓ¢¹ú°×È˾ßÓÐZ+2µÈ λ»ùÒòµÄIDDM»¼Õߣ¬ÆäAR»ùÒò5¡äÅÔ²àµ÷¿ØÇø¿ÉÄÜ·¢ÉúÁ˱äÒ죬ֵµÃ½øÒ»²½Ñо¿¡£
Òª¶Ô¿ÉÄÜ·¢ÉúµÄ±äÒì½øÐÐ̽Ë÷£¬Ê×ÏȱØÐëɸѡ³öº¬Z-2»òZ+2µÈλ»ùÒòµÄ²¡ÈË¡£KoµÈ[1]ºÍHeesomµÈ[2]²ÉÓõķ½·¨ÊÇÌáÈ¡»ùÒò×éDNAºóÉè¼ÆÒ»¶ÔÒýÎï½øÐÐPCRÀ©Ôö£¬ ÆäÖÐÉÏÓÎÒýÎïÓÃ[¦Ã-32P]ATP½øÐÐÄ©¶Ë±ê¼Ç£¬À©Ôö²úÎï¾5%¼×õ£°·/ÄòËØ¾Û±û Ï©õ£°·Äý½ºµçÓ¾£¬Äý½º¸ÉÔïºó½øÐзÅÉä×ÔÏÔÓ°£¬È»ºó¸ù¾Ý²»Í¬ÑùÆ·Ç¨ÒÆ¾àÀëµÄ²îÒìÒÔÈ·¶¨¸÷ ÖÖµÈλ»ùÒò¡£´Ë·¨Ðè´óÁ¿Ê¹Ó÷ÅÉäÐÔÍ¬Î»ËØ£¬³É±¾¸ß£¬ºÄʱ³¤£¬²»ÀûÓÚ´ó¹æÄ£É¸Ñ¡¡£
Õë¶ÔÉÏÊöÎÊÌ⣬±¾ÊµÑéÊÒÄ⽨Á¢Ò»Ì×Äܼò±ã¡¢¿ìËÙ¡¢×¼È·É¸Ñ¡Î¢ÎÀÐÇDNAµÈλ»ùÒòµÄ·½·¨£¬ ¶ÔAR»ùÒòת¼ÆðʼµãÉÏÓÎ(AC)n¶þºËÜÕËáÖØ¸´ÐòÁÐÖеĸ÷ÖÖµÈλ»ùÒò½øÐÐɸѡ¡£
1 ²ÄÁÏÓë·½·¨
1.1 ²ÄÁÏ
1.1.1 ±ê±¾ ÈËÍâÖÜѪ£¬°üÀ¨Õý³£ÈË41Àý£¬2ÐÍÌÇÄò²¡(NIDDM)»¼Õß53 Àý¡£Ñù±¾¾ùÈ¡×ÔºþÄÏÒ½¿Æ´óѧ¸½ÊôÏæÑÅÒ½Ôº¡£
1.1.2 ÊÔ¼Á TaqøΪÉϺ£SangonÉúÎ﹤³Ì¹«Ë¾²úÆ·£»²âÐòÊÔ¼ÁºÐ²ÉÓÃPro mega
1.2 ·½·¨
1.2.1 º¬(AC)nÖØ¸´ÐòÁÐÆ¬¶ÏµÄPCRÀ©Ôö ×ÔÍâÖÜѪ°×ϸ°ûÖÐÌáÈ¡»ùÒò×éDNA[3]£¬Éè¼ÆÒýÎï5¡ä-GAATCTTAACATGCTCTGAACC-3¡ä¼°5¡ä-GCCCAGCCCTATACCTAGT-3¡ä ½øÐÐPCRÀ©Ôö£¬µÃ³¤¶È132¡«144bpµÄDNAƬ¶Ï¡£PCR·´Ó¦Ìõ¼þ[1]ΪԤ±äÐÔ94¡æ 3min£¬¼ÌÖ®35¸öÖÜÆÚ£¬Ñ»·Ìõ¼þΪ±äÐÔ94¡æ 1min£¬ÍË»ð¼°ÑÓÉì61¡æ 1min¡£ÖÕÄ© ÑÓÉì10min¡£PCR²úÎïÓ릵X174DNA/Hae¢ó MarkersÐÐ8%¾Û±ûÏ©õ£°·Äý½ºµçÓ¾£¬ÒÔ³õ²½È·¶¨ Ä¿µÄ²úÎïµÄƬ¶Ï´óС¡£
1.2.2 ÓÃ×÷ɸѡ±ê×¼µÄµÈλ»ùÒòµÄÈ·¶¨ ѡȡµÈλ»ùÒòΪ´¿ºÏ×Ó¡¢PCR²ú ÎïÔÚ±äÐÔ½ºÉÏÇ¨ÒÆËٶȲ»Í¬µÄDNA±ê±¾£¬ÐÐÉÏÊöPCR·´Ó¦ºó£¬ÓÃ8%¾Û±ûÏ©õ£°·Äý½ºµçÓ¾´¿»¯ [4]¡£ÒÔ´Ë´¿»¯»ØÊÕÆ¬¶ÏΪ²âÐòÄ£°å£¬ÒÔ[¦Ã-32P]ATP-T4¾ÛºËÜÕËἤ ø·¨±ê¼ÇÉÏÓβàÒýÎÓÃPromega fmol¡ð RDNA²â Ðòϵͳ²âÐòÒÔÈ·¶¨ÑùÆ·Ëùº¬µÈλ»ùÒòµÄÖÖÀà¡£¾²âÐòÈ·¶¨µÄµÈλ»ùÒòÔÙÐбäÐÔ½ºµçÓ¾£¬ÒÔÑé Ö¤¸÷ÖÖµÈλ»ùÒòµÄ´óС˳Ðò¡£
1.2.3 ¸÷ÖÖµÈλ»ùÒòµÄɸѡ Óþ²âÐò֤ʵµÄµÈλ»ùÒò(ÈçZ-2)Ϊ²Î¿¼±ê ×¼(marker)£¬ÒÔ´ýɸѡÑùÆ·µÄPCR²úÎïÓë¸Ã±ê×¼ÐÐ12%ÄòËØ-¼×õ£°·¾Û±ûÏ©õ£°·Äý½ºµçÓ¾ [5]£¬Ëæ¼´ÒøÈ¾[6]È»ºó½«Äý½ºÕæ¿Õ¸ÉÔï¡£¸ù¾ÝÇ¨ÒÆ¾àÀëÈ·¶¨ËùÊôµÈλ»ùÒò¡£
2 ½á ¹û
PCRÀ©ÔöºóµÃ³¤¶È132¡«144bpµÄDNAƬ¶Ï(ͼ1)¡£¾²âÐòÈ·Ö¤ÁËZ+4£¬Z+2£¬Z£¬Z-2¼°Z-4µÈ 5ÖÖ µÈλ»ùÒò£¬Æä(AC)nÖØ¸´Êý·Ö±ðΪ26£¬25£¬24£¬23¼°22£»¼î»ùÊý·Ö±ðΪ142£¬140£¬138 £¬1 36¼°134(ͼ2)¡£²»Í¬µÈλ»ùÒòÔÚ±äÐÔ½ºÉÏÇ¨ÒÆËÙ¶ÈÓë²âÐò½á¹ûÒ»Ö£¬¼´°´Z+4£¬Z+2£¬Z£¬Z- 2¼°Z-4˳Ðò¼î»ùÊýµÝ¼õ£¬Ç¨ÒÆËٶȵÝÔö(ͼ3)¡£53ÀýNIDDM»¼ÕßÓë41ÀýÕý³£ÈËÖи÷ÖÖµÈλ»ù Òò·Ö²¼Çé¿ö¼û¸½±í¡£µÈλ»ùÒòµÄɸѡ¼ûͼ4(ÒÔZ-2ΪÀý)¡£
ͼ1 PCR²úÎïµÄ¼ø¶¨ M£º¦µX174DNA/Hae ¢ó·Ö×ÓÁ¿±ê×¼£»1¡«5£ºËæ»úѡȡµÄÕý³£¶ÔÕÕÑùÆ·£»6¡«10£ºËæ»úѡȡµÄ2ÐÍÌÇÄò²¡»¼ÕßÑùÆ·
Fig. 1 Identification of PCR products M : ¦µX174DNA/Hae¢ó Markers; Lane 1¡«5: Control subjects selected at random; Lane 6¡«10: Patients with NIDDM selected at random
ͼ2 Z-4£¬Z-2£¬Z£¬Z+2ºÍZ+4 5ÖÖµÈλ»ùÒòÐò Áвⶨ 5ÖÖµÈλ»ùÒòµÄACÖØ¸´Êýn·Ö±ðΪ22£¬23£¬24£¬25ºÍ26¡£
Fig. 2 Sequence analysis of 5 alleles Z -4,Z-2,Z,Z+2 and Z+4 Repeat numbers of 5 alleles are 22,23,24,25 and 26 respe ctively
ͼ3 Z+4£¬Z+2£¬Z£¬Z-2ºÍZ-4ÎåÖÖµÈλ»ù ÒòÔÚ12%±äÐÔ½ºÉÏÇ¨ÒÆËٶȶԱÈ
Fig. 3 Comparison of shift mobility on 12% denaturing gel of five alleles Z+4,Z+2,Z,Z-2 and Z-4
ͼ4 Z-2µÈλ»ùÒòµÄɸѡ
Fig. 4 Screening of Z-2 allele
¸½±í ÖйúÈËAR»ùÒò(AC)nÖØ¸´ÐòÁи÷ÖÖµÈλ»ùÒòµÄ·Ö²¼¢Ù
Z-6
Z-4
Z-2
Z
Z +2
Z+4
Z+6
total
NIDDM»¼Õß(n=53)
0
0.066(7)
0.236(25)
0.302(32)
0.2 74(29)
0.104(11)
0.019(2)
1(106)
Õý³£¶ÔÕÕ(n=41)
0
0.098(8)
0.256(21)
0.329(27)
0.2 32(19)
0.073(6)
0.012(1)
1(82)¡þ
¢Ù±íÖÐÊý¾ÝΪ°Ù·ÖÂÊ£¬À¨ºÅÄÚΪȾɫÌåÊý
3 ÌÖ ÂÛ
½«PCR²úÎï´¿»¯ºóÖ±½Ó²âÐò£¬²âÐòÄ£°å×÷Ϊɸѡ±ê×¼£¬³ä·Ö±£Ö¤ÁËɸѡ½á¹ûµÄ׼ȷÐÔ¡£ÓÉÓÚ Ä£°åΪ(AC)nÖØ¸´ÐòÁУ¬²»º¬GºÍT£¬²ÉÓÃÊÖ¹¤²âÐò¿É»ñµÃÇåÎúµÄͼÆ×¡£±ÊÕß²ÉÓÃÒøÈ¾ÏÔÉ«·¨ £¬¼È½µµÍ³É±¾£¬ÓÖ·½±ã²Ù×÷£¬¿ÉÅųý·ÅÉäÐÔÍ¬Î»ËØµÄÎÛȾ¡£ÒøÈ¾·¨²Ù×÷¼ò±ã¡¢Ìõ´øÇåÎúÇÒÒø ȾºóµÄÄý½º¾Õæ¿Õ¸ÉÔïºó¿É³¤ÆÚ±£´æ¡£ÓÉÓÚÔÚ±äÐÔ½ºÉÏACÁ´ÓëGTÁ´·ÖÀ룬¹Êÿ¸öÑùÆ·ÔÚ±äÐÔ ½ºµçÓ¾ÔÙ¾ÒøÈ¾ÏÔÉ«ºó¾ù¿É¼ûÁ½ÌõÇø´ø£¬µ«²¢²»Ó°Ïì¸÷ÖÖµÈλ»ùÒòµÄɸѡ¡£¶Ô53ÀýNIDDM »¼ÕߺÍ41ÀýÕý³£È˵Èλ»ùÒòµÄɸѡ½á¹û£¬¼´¸÷ÖÖµÈλ»ùÒòµÄ·Ö²¼»úÂÊ£¬ÓëKoµÈÈ˺ÍHeasomµÈ È˱¨µÀµÄ½á¹ûÏà·û¡£ÓÉÓÚZ-6µÈλ»ùÒò³öÏֵĻúÂʺÜС£¬¹ÊÎ´ÔøÉ¸»ñ¡£Í¨¹ýÓëKoµÈÈ˵ķÅÉä ×ÔÏÔӰͼÏñ[1]±È½Ï¿ÉÒÔ¿´³ö£¬ÒøÈ¾Í¼Ïñ(ͼ4)±È·ÅÉä×ÔÏÔÓ°ÏñÇø´ø¸üÇåÎú¡£´Ë·¨ ÊÊÓÃÓÚÆäËü¶þºËÜÕËáÖØ¸´ÐòÁеÈλ»ùÒòµÄɸѡ¡£
»ù½ðÏîÄ¿£º¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð×ÊÖú×ÊÖú¿ÎÌâ(39670352)
×÷Õß¼ò½é£ºÀîÇå½â(1966-)£¬ÄУ¬¸±½ÌÊÚ
²Î¿¼ÎÄÏ×£º
[1]Ko BCB, Lam KSL, Wat NMS, et al. An(AC)n dinucleotide repeat polymorphic marker at the 5¡ä end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients[J]. Diabetes, 1995,44(7):727-732.
[2]Heesom AE, Millward A, Demaine AG. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymor phism at the 5¡ä end of the aldose reductase gene[J]. J Neurol Neurosurg Psych iatry, 1998,64:213-216.
[3]Reardon W, Ross RJM, Sweeney MG, et al. Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA[J]. Lancet, 1992,340:1376-1379.
[4]Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A Laboratory Manu al[M]. 2nd ed. New York: Cold Spring Harbor Laboratory Press, 1989:6.36-6.44.
[5]Litt M, Hauge XY, Sharma V. Shadow bands seen when typing polymorphic din ucleotide repeats: Some causes and cures[J]. Biotechniques, 1993,15(2):280-283 .
[6]Budowle B, Chakraborty R, Giusti AM, et al. Analysis of the VNTR locu s DIS80 by the PCR followed by high-resolution PAGE[J]. Am J Hum Genet, 1991, 48:137-144.
ÊÕ¸åÈÕÆÚ£º1999-02-06 (ÎÄÕ³ö´¦£ººþÄÏÒ½¿Æ´óѧѧ±¨ 2000ÄêµÚ1ÆÚµÚ25¾í)
ÍÆ¼öÔĶÁ
¼²²¡´óÈ«¸ü¶à>>
½¡¿µÍ¼Æ×
- ÓÑÇéÁ´½Ó